Cambrex Corp (NYSE:CBM)

40.42
Delayed Data
As of May 27
 +0.93 / +2.36%
Today’s Change
15.76
Today|||52-Week Range
44.22
+86.96%
Year-to-Date
SECTOR
Process Industries
INDUSTRY
Chemicals: Specialty
MARKET CAP
$1.2B

Company Description

Cambrex Corp. is a life sciences company that provides products, services and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies its products and services worldwide to innovator and generic pharmaceutical companies. The company's products include active pharmaceutical ingredients (APIs) and intermediates, generic and branded APIs, controlled substances, chiral compounds, high potency and technology-enhanced APIs, and fine chemicals. The company supplies generic and branded APIs for various indications, including pain management, cardiovascular, central nervous system, endocrine, gastrointestinal, integumentary, respiratory and urinary. It sells its products directly, as well as through independent agents to various pharmaceutical and generic drug companies. Cambrex was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in December 1981 and is headquartered in East Rutherford, NJ.

Contact Information

Cambrex Corp.
One Meadowlands Plaza
East Rutherford New Jersey 07073
P:(201) 804-3000
Investor Relations:
(201) 804-3037

Employees

Shareholders

Other institutional50.09%
Mutual fund holders42.38%
Individual stakeholders3.23%

Top Executives

Steven M. KloskPresident, Chief Executive Officer & Director
Shawn P. CavanaghChief Operating Officer & Executive Vice President
Gregory P. SargenChief Financial Officer & Executive Vice President
James G. FarrellVice President & Controller
Samantha M. HanleySecretary, Vice President & General Counsel

To view my watchlist

Not a member yet?

Sign up now for a free account